question stringlengths 37 360 | answer stringlengths 66 1.16k |
|---|---|
What are the mutated genes in TCGA breast cancer cohort data ? | The mutated genes in TCGA breast cancer cohort data with stop_gained effect in the stage iib male patients are CCDC57, OR6N1, MYCBP2, MYH7, PRKG2, VCAN |
What are the mutated genes in TCGA breast cancer cohort data ? | The mutated genes in TCGA breast cancer cohort data with stop_gained effect in the stage iiia male patients are FRG2C TRIM42 KIAA1109 SULT1A1 |
What are the mutated genes in TCGA breast cancer cohort data ? | The mutated genes in TCGA breast cancer cohort data with stop_gained effect in the stage ii male patients ARID1AIL9R. |
What are the mutated genes in TCGA breast cancer cohort data ? | The mutated genes in TCGA breast cancer cohort data with stop_gained effect in stage iv black patients and age 50-65 are MIA3 VPRBP CEP112 GBE1 FLNC PTCHD3 KLHL1 KLHL33 SAV1 LTBP4 ADCY10 |
What are the mutated genes in TCGA breast cancer cohort data ? | Tthe mutated genes in TCGA breast cancer cohort data with stop_gained effect in stage iv patients and age 65-80 are BMPR2 RAPGEF3 SLAMF8 SPRY3 |
what are the mutated genes in TCGA breast cancer cohort data ? | The mutated genes in TCGA breast cancer cohort data with stop_gained effect in stage iv patients and age 35-50 are CSMD2 ACOT11 CACNA1E FRAS1 ANKRD55 KMT2C LRP5 LRP5 CLTC ZNF721 USP32 ISM1 |
What are the mutated genes in TCGA breast cancer cohort data ? | the mutated genes in TCGA breast cancer cohort data with stop_gained effect in 60-75 aged females with stage iv and post menopausal_status are GRM7 BMPR2 RAPGEF3 MIA3 GBE1 FLNC PTCHD3 KLHL1 KLHL33 SAV1 LTBP4 PPARGC1B RABGAP1 TOX4 AHNAK2 CBFB APOL1 |
What are the mutated genes in TCGA breast cancer cohort data ? | The mutated genes in TCGA breast cancer cohort data with stop_gained effect in 65-80 aged females with stage iv and post menopausal_status group of patients are BMPR2 RAPGEF3 SLAMF8 SPRY3 |
What are the mutated genes in TCGA breast cancer cohort data ? | The mutated genes in TCGA breast cancer cohort data with stop_gained effect in females with stage iv and post menopausal_status group, race as black or african american and who are dead are MIA3 GBE1 FLNC PTCHD3 KLHL1 KLHL33 SAV1 LTBP4 ADCY10 |
What is the percentage of patients in TCGA breast cancer cohort who have BRCA1 mutation | The percentage of patients in TCGA breast cancer cohort who have BRCA1 mutation are 2.6% |
What is the percentage of patients in TCGA breast cancer cohort who have BRCA2 mutation | The percentage of patients in TCGA breast cancer cohort who have BRCA2 mutation are 2.4% |
What is the percentage of patients in TCGA breast cancer cohort who have BRCC3 mutation | The percentage of patients in TCGA breast cancer cohort who have BRCC3 mutation are 0.5% |
What are the percentage of genes in TCGA breast cancer cohort data that have mutation with p.E545K mutation in PIK3CA | the percentage of genes in TCGA breast cancer cohort data that have mutation with p.E545K mutation in PIK3CA is 6.07% |
What is the effect of mutation chr13:A 38851084 G on the TCGA breast cancer cohort data | The effect of mutation chr13:A 38851084 G on the TCGA breast cancer cohort data is missense_variant |
What are the prevalent mutations present in breast cancer patients in TCGA breast cancer cohort data ? | The prevalent frameshift mutations present in 26 year old breast cancer patients in TCGA breast cancer cohort data who are alive are GATA3 BCDIN3D KIAA0430 MAP2K4 MYO18B NRK |
What are the prevalent mutations present in breast cancer patients in TCGA breast cancer cohort data ? | The prevalent stop_gained mutations present in 26 year old breast cancer patients in TCGA breast cancer cohort data who are alive are ARID1A CFTR SYNM |
What are the prevalent mutations present in breast cancer patients in TCGA breast cancer cohort data ? | The prevalent frameshift_variant mutations present in age group 65-80 year old breast cancer patients in TCGA breast cancer cohort data who are in stage iv are LAMC1,ABHD6,RBM47,MINK1,KIFAP3,MDGA1,KMT2C,ZBTB10,EFR3A,PTEN,CDKN1B,GALNT14,PPWD1,EXT1,SLCO1A2 |
In which stages of breast cancer stop_lost mutation effect is observed ? | The stage of breast cancer in asian population where stop_lost mutation effect is observed is stage iib stage iiia |
In which stages of breast cancer stop_lost mutation effect is observed ? | stage iia stage iia stage iv stage i - are the stages of breast caner in black polulation is the stop_lost mutation effect is observed |
In which stages of breast cancer stop_lost mutation effect is observed ? | stage iiia stage i stage iiib - are the stages of breast cancer in white population is the stop_lost mutation effect is observed where the patient is dead |
In which stages of breast cancer stop_lost mutation effect is observed ? | stage iib is the stage of breast cancer in asian population where the stop_lost mutation effect is observed and the patient is alive. |
How many genes are there in TCGA breast cancer cohort data that have reference allele -? | The number of genes are there in TCGA breast cancer cohort data that have reference allele - is 2495 |
What is the number of patients in TCGA breast cancer cohort data with amino acid change p.R1485W? | The p.R1485W mutation was found in a female 80 year old patient at stage iia |
What is the number of genes in TCGA Breast Cancer cohort data that are mutated on chr11 ? | The number of genes in TCGA breast cancer cohort data is 975 that are muted on chr11 where mutation effect is missense_variant |
What is the number of genes in TCGA Breast Cancer cohort data that are mutated on chr10 ? | The number of genes in TCGA breast cancer cohort data is 55 that are muted on chr10 where age of the patient is 74 years |
What is the percentage of patients in TCGA breast cancer cohort data with respect to their mutation effect ? | There are 23.35% of patients in TCGA breast cancer cohort data with mutation effect non_coding_transcript_variant and Alive in stage iia |
What is the percentage of patients in TCGA breast cancer cohort data with respect to their mutation effect ? | There are 12.04% percentage of patients in TCGA breast cancer cohort data with mutation effect downstream_gene_variant and alive in stage iia |
What is the percentage of patients in TCGA breast cancer cohort data with respect to their mutation effect ? | There are 11.62% percentage of petients in TCGA breast cancer cohort data with mutation effect inframe_deletion and Alive in stage iia |
What is the percentage of patients in TCGA breast cancer cohort data with respect to their mutation effect ? | There are 4.08% percentage of patients in TCGA breast cancer cohort data with mutation effect inframe_insertion and Alive in stage iia |
what is the percentage of patients in TCGA breast cancer cohort data with respect to their age and race ? | There are 10.05% of patients in TCGA breast cancer cohort data whos age less than 60 and are of race black or african american |
What is the percentage of patients in TCGA Breast cancer cohort data with respect to their age in stage ? | There are 0.1% of patients in TCGA breast cancer cohort data have age above 80 and are in stage iv |
What are the details of TCGA Breast cancer cohort data with respect to menopause status ? | There are 31 patients in the TCGA breast cancer cohort data have indeterminate menopause status |
Are there any mutations having effect missense_variant In TCGA Breast cancer cohort data how many ? | There are 334 mutations on gene TP53 have effect missense_variants |
Which are the mutated genes in TCGA Breast cancer cohort data on specific to patients who are dead ? | LHCGR ZEB2 IL36G SMEK2 USP34 BIRC6 - These are mutated genes in TCGA breast cancer cohort data on chr2 have effect inframe_deletion and the patient is dead |
What is the percentage of patients in the TCGA Breast cancer cohort data with respect to race and mutated gene ? | There are 1.78% patients in the TCGA breast cancer cohort data have race white & gene BRCA1 |
what is the distribution of age of patients in TCGA Breast cancer cohort dataset ? | There are a total of 955 patients. The percentage distribution of age between 25-40 is 9.21%, between 41-60 is 47.53%, between 61-80 is 39.37% and between 81-90 is 3.87%. |
what is the distribution of patients in TCGA Breast cancer cohort across different races ? | There are a total of 955 patients. The percentage race distribution of white is 69.52%, black or african american is 16.64%, ,asian is 5.75% , american indian or alaska native is 0.10% and not reported is 7.95%. |
What is the percentage distribution of the female patients in different stages of menopause ? | There are a total of 944 female patiets. The percentage distribution is Pre menopausal 21.92%, post menopausal 64.19%Peri menopausal 3.6%. Where are about 3.6% are Indeterminate and 6.9% are unknown |
What are the ERBB2 variants for Triple-receptor Negative Breast Cancer ? | L725S, L740S are the ERBB2 variants for Triple-receptor Negative Breast Cancer |
What are therapies in Breast Cancer ? | Durvalumab is therepy associated with XRCC3 variant in Triple-receptor Negative Breast Cancer |
What are therapies in Breast Cancer ? | Increased cisplatin sensitivity in ORC1 mutant PDX models, compared to wildtype cells is therepy associated with ORC1 variant in Triple-receptor Negative Breast Cancer and its effect |
What are therapies in Breast Cancer ? | LAG3 expression is favorable prognostic factor associated with Estrogen-receptor Negative Breast Cancer. Overexpression of RET is also associated with Estrogen-receptor Negative Breast Cancer and drug Vandetanib induced tumor regression in PDX models with high expression of RET or EGFR. |
Which point mutation is obersved in case after extensive treatment with hormonal therapy (aromatase inhibition) in Estrogen-receptor Positive Breast Cancer patients ? | ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition) |
What is the reason for mutation in Estrogen-receptor Positive Breast Cancer patients ? | The reason for ESR1 S463P mutation in Estrogen-receptor Positive Breast Cancer patients is prolonged hormonal therapy (aromatase inhibotor) |
What are therapies in Breast Cancer ? | Drug Temsirolimus showed complete response> 3 yrs in a breast cancer patient |
what is known for RB1 frameshift mutation (RB1 p.M695fs*26) in Estrogen-receptor Positive Breast Cancer patient ? | In a preclinical study Palbociclib resistant Estrogen-receptor Positive Breast Cancer cell lines showed decreased pRb protein levels |
HRD is a known biomarker for BRCA that can guide the treatment regimen for patients.To identify patients who could potentially benefit from PARP inhibitors or other DDR-inducing drugs beyond those withBRCA1/2mutation is a relevant clinical topic. ARID1A gene is one of the biomarkers for HRD. what mutations are observed... | R1989* is identify patients who could potentially benefit from PARP inhibitors or other DDR-inducing drugs beyond those with BRCA1/2 mutation is a relevant clinical topic. ARID1A gene is one of the biomarkers for HRD where muttation are observerd in breast cancer patiends in this genes |
what are the driver mutations in breast cancer patients associated with HRD ? | ARID1A is associated with HRD and truncating mutation, frameshift mutation and splice variants are driver mutations such as R1989*, E1726*, T1514Rfs*13, X1136_splice etc |
what are the driver point mutations asssociated with breast cancer ? | N2875S and R337H are the driver point mutations in ATM gene asssociated with breast cancer |
what are the gene associated with homologous recombination deficiency ? | The genes associated with homologous recombination deficiency are ARID1A, ATM, ATRX, BAP1, BARD1, BLM, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, WRN |
what are the inherited gene mutations that can increase breast cancer risk ? | The most common cause of hereditary breast cancer is an inherited mutation in the BRCA1 or BRCA2 gene. In normal cells, these genes help make proteins that repair damaged DNA. Mutated versions of these genes can lead to abnormal cell growth, which can lead to cancer.If you have inherited a mutated copy of either gene f... |
what are the inherited gene mutations that can increase breast cancer risk ? | TheATMgene normally helps repair damaged DNA (or helps kill the cell if the damaged can't be fixed). Inheriting 2 abnormal copies of this gene causes the disease ataxia-telangiectasia. Inheriting one abnormal copy of this gene has been linked to a high rate of breast cancer in some families. |
what are the inherited gene mutations that can increase breast cancer risk ? | ThePALB2gene makes a protein that interacts with the protein made by theBRCA2gene. Mutations in this gene can lead to a higher risk of breast cancer. |
what are the inherited gene mutations that can increase breast cancer risk ? | TheTP53gene helps stop the growth of cells with damaged DNA. Inherited mutations of this gene causeLi-Fraumeni syndrome. People with this syndrome have an increased risk of breast cancer, as well as some other cancers such as leukemia, brain tumors, and sarcomas (cancers of bones or connective tissue). This mutation is... |
what are the inherited gene mutations that can increase breast cancer risk ? | TheCHEK2geneis another gene that normally helps with DNA repair. ACHEK2mutation increases breast cancer risk. |
what are the inherited gene mutations that can increase breast cancer risk ? | ThePTENgene normally helps regulate cell growth. Inherited mutations in this gene can causeCowdensyndrome, a rare disorder that puts people at higher risk for both cancer and benign (non-cancer) tumors in the breasts, as well as growths in the digestive tract, thyroid, uterus, and ovaries. |
what are the inherited gene mutations that can increase breast cancer risk ? | Inherited mutations in this gene causehereditary diffuse gastric cancer, a syndrome in which people develop a rare type of stomach cancer. Women with mutations in this gene also have an increased risk of invasive lobular breast cancer. |
what are the inherited gene mutations that can increase breast cancer risk ? | Defects in this gene can lead toPeutz-Jeghers syndrome. People affected with this disorder have pigmented spots on their lips and in their mouths, polyps (abnormal growths) in the urinary and digestive tracts, and a higher risk of many types of cancer, including breast cancer. |
What are the FDA approved therapies and response rate available for metastatic triple negative breast cancer patient who had received two prior treatments for metastatic diasease ? | The FDA approved Trodelvy based on the results of a clinical trial of 108 patients. The efficacy of Trodelvy was based on the overall response rate (ORR) which reflects the percentage of patients that had a certain amount of tumor shrinkage. The ORR was 33.3%, with a median duration of response of 7.7 months. Of the p... |
What are the FDA approved therapies available for metastatic triple negative breast cancer patient who is not responding to other treatments ? | Metastatic triple-negative breast cancer is an aggressive form of breast cancer with limited treatment options. Chemotherapy has been the mainstay of treatment for triple-negative breast cancer. The approval of Trodelvy represents a new targeted therapy for patients living with this aggressive malignancy |
What are the FDA approved therapies available for metastatic triple negative breast cancer patient who is not responding to other treatments ? | Trodelvy is FDA approved therapy for metastatic triple negative breast cancer patient who is not responding to other treatments.Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate, meaning that the drug targets the Trop-2 receptor that helps the cancer grow, divide and spread, and is linke... |
What is the response rate of Trodelvy for metastatic triple negative breast cancer patient who had received two prior treatments for metastatic diasease ? | a clinical trial of 108 patients showed The efficacy of Trodelvy was based on the overall response rate ORR) which reflects the percentage of patients that had a certain amount of tumor shrinkage. The ORR was 33.3%, with a median duration of response of 7.7 months. Of the patients with a response to Trodelvy, 55.6% mai... |
What is the primary efficacy endpoint of sacituzumab govitecan for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease ? | The primary efficacy endpoint was progression-free survival (PFS) in patients without brain metastases at baseline as measured by a blinded, independent, centralized review assessed using RECIST 1.1 criteria. Additional efficacy endpoints included PFS for the full population (with and without brain metastases) and ove... |
what is the FDA approved therapy for residual invasive HER2 positive breast cancer after neoadjuvant therapy ? | Trastuzumab emtansine(T-DM1) for patients with early-stage high-risk HER2-positive breast cancer with residual disease after neoadjuvant therapy with trastuzumab and taxane-based treatment |
What are the most common adverse reactions (incidence >25%) in patients receiving sacituzumab govitecan ? | Most common adverse reactions (incidence >25%) in patients receiving sacituzumab govitecan are nausea, neutropenia, diarrhea, fatigue, alopecia, anemia, vomiting, constipation, rash, decreased appetite, and abdominal pain |
What is side effect associated with CDK4/6 inhibitors used to treat advanced breast cancer patients ? | severe pulmonary inflammation is side effect associated with CDK4/6 inhibitors used to treat advanced breast cancer patients |
What type of targeted therapy is used to treat HER2-negative breast cancer with mutations in the BRCA1 or BRCA2 gene ? | PARP inhibitors targeted therapy is used to treat HER2-negative breast cancer with mutations in the BRCA1 or BRCA2 gene? |
What hormone therapy is recommended for male breast cancer patients with estrogen-receptor and progesterone-receptor positive breast cancer ? | Tamoxifen hormone therapy is recommended for male breast cancer patients with estrogen-receptor and progesterone-receptor positive breast cancer |
What kind of combination immunotherapy can be recommended for triple-negative breast cancer ? | PD-1/PD-L1 immune checkpoint inhibitors combination immunotherapy recommended for triple-negative breast cancer |
What therapy is effective in recurrent breast cancer patients ? | Lapatinib monotherapy and combination therapy is effective in recurrent breast cancer patients with HER2 mutation havinf brain metastases |
README.md exists but content is empty.
- Downloads last month
- 3